

Monika Wagner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6058438/publications.pdf>

Version: 2024-02-01

16
papers

914
citations

840776

11
h-index

1058476

14
g-index

16
all docs

16
docs citations

16
times ranked

872
citing authors

#	ARTICLE	IF	CITATIONS
1	Moving Towards Accountability for Reasonableness – A Systematic Exploration of the Features of Legitimate Healthcare Coverage Decision-Making Processes Using Rare Diseases and Regenerative Therapies as a Case Study. <i>International Journal of Health Policy and Management</i> , 2019, 8, 424-443.	0.9	10
2	Development of a Framework Based on Reflective MCDA to Support Patient–Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States. <i>Advances in Therapy</i> , 2018, 35, 81-99.	2.9	14
3	Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient–Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context. <i>Advances in Therapy</i> , 2018, 35, 1215-1231.	2.9	7
4	Authors’ Reply to Gandjour: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation”. <i>Pharmacoeconomics</i> , 2017, 35, 605-606.	3.3	0
5	EXPLORING VALUES OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES USING REFLECTIVE MULTICRITERIA AND RARE DISEASE CASE. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 504-520.	0.5	14
6	Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA. <i>BMC Cancer</i> , 2017, 17, 272.	2.6	34
7	Identifying Value(s): A Reflection on the Ethical Aspects of MCDA in Healthcare Decisionmaking. , 2017, , 29-46.		9
8	Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation. <i>Pharmacoeconomics</i> , 2016, 34, 285-301.	3.3	53
9	Pragmatic Multicriteria Decision Analysis (MCDA) Combined With Advanced Pharmacoepidemiology for Benefit-Risk Assessments of Medicines Adapted to the Real-Life Constraints of Regulators: Development and Case Study. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 620-631.	1.6	8
10	WHICH CRITERIA ARE CONSIDERED IN HEALTHCARE DECISIONS? INSIGHTS FROM AN INTERNATIONAL SURVEY OF POLICY AND CLINICAL DECISION MAKERS. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 456-465.	0.5	80
11	Bridging Health Technology Assessment (HTA) and Efficient Health Care Decision Making with Multicriteria Decision Analysis (MCDA). <i>Medical Decision Making</i> , 2012, 32, 376-388.	2.4	131
12	Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa. <i>Cost Effectiveness and Resource Allocation</i> , 2012, 10, 2.	1.5	36
13	From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking. <i>Cost Effectiveness and Resource Allocation</i> , 2012, 10, 9.	1.5	163
14	Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. <i>BMC Health Services Research</i> , 2011, 11, 329.	2.2	92
15	Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patients. <i>Cost Effectiveness and Resource Allocation</i> , 2010, 8, 4.	1.5	84
16	Evidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applications. <i>BMC Health Services Research</i> , 2008, 8, 270.	2.2	179